79 related articles for article (PubMed ID: 17416000)
21. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kharmate G; Rajput PS; Watt HL; Somvanshi RK; Chaudhari N; Qiu X; Kumar U
Biochim Biophys Acta; 2011 Jun; 1813(6):1172-89. PubMed ID: 21419811
[TBL] [Abstract][Full Text] [Related]
22. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
23. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
[TBL] [Abstract][Full Text] [Related]
24. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
25. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
27. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
28. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
29. Paeonol induces the apoptosis of the SGC‑7901 gastric cancer cell line by downregulating ERBB2 and inhibiting the NF‑κB signaling pathway.
Fu J; Yu L; Luo J; Huo R; Zhu B
Int J Mol Med; 2018 Sep; 42(3):1473-1483. PubMed ID: 29845222
[TBL] [Abstract][Full Text] [Related]
30. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
31. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
32. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
33. Ursolic acid induces U937 cells differentiation by PI3K/Akt pathway activation.
Deng L; Zhang R; Tang F; Li C; Xing YY; Xi T
Chin J Nat Med; 2014 Jan; 12(1):15-9. PubMed ID: 24484591
[TBL] [Abstract][Full Text] [Related]
34. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Mukohara T; Civiello G; Johnson BE; Janne PA
Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells.
Moon DO; Kim MO; Lee JD; Choi YH; Lee MK; Kim GY
Acta Pharmacol Sin; 2007 Aug; 28(8):1205-14. PubMed ID: 17640484
[TBL] [Abstract][Full Text] [Related]
37. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
[TBL] [Abstract][Full Text] [Related]
38. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
39. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
[TBL] [Abstract][Full Text] [Related]
40. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
